# Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00558285** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 257 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** indacaterol/glycopyrrolate
- **DRUG:** indacaterol
- **DRUG:** glycopyrrolate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00558285
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2012-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558285, "Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00558285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*